Avanir Pharmaceuticals: Uncovering Nuedexta’s Potential

Avanir’s drug, Nuedexta, was recently approved by the FDA as a treatment for pseudobulbar affect (PBA), a condition characterized by uncontrolled bouts of laughing and crying. Market analysis conducted for Nuedexta revealed that 50% of ALS patients are purported affected by PBA.

Click here to read more.

Share this: